This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For months, hydroxychloroquine, has been at the centre of much interest as potential preventative measure and for treating patients with Covid-19.
The anti-malarial drug has been promoted by Brazil's President Jair Bolsonaro and his by his US counterpart Donald Trump who even took it himself for a while to ward off infection.
The ongoing interest in the drug has led shortages and rising prices which directly impacted those taking the drug already for autoimmune conditions like lupus and rheumatoid arthritis.
While recent large scale trials have shown that hydroxychloroquine is not effective as a treatment some countries have continued to promote its use within their healthcare systems.
With so many twist and turns, the question is where do we stand now with hydroxychloroquine?
Produced, edited and presented by Jameisha Prescod
Graphics by George Wafula
Executive producers: Miriam Quansah and Marko Zoric